Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Levels of Health Promotion and Illness Prevention01:26

Levels of Health Promotion and Illness Prevention

14.1K
Health promotion allows a person to control the determinants of health, resulting in an improved health status. It enhances the quality of life and reduces premature deaths. Health promotion and illness prevention programs help people make beneficial choices to reduce the risk of disease and disabilities. There are three health promotion and illness prevention levels: primary, secondary, and tertiary prevention.
In primary prevention, actions taken before disease onset prevent the disease from...
14.1K
Preventive Healthcare Services01:30

Preventive Healthcare Services

1.8K
Preventive healthcare services keep people healthy via frequent check-ups, screening, and counseling. They primarily aid in disease prevention rather than treating an acute or chronic illness. Preventive treatment also keeps individuals productive and energetic, allowing them to work well into their retirement years. Examples of preventive care services include:
1.8K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.7K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

296
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
296

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

UK consensus on pregnancy in multiple sclerosis: An update to 'Association of British Neurologists' guidance.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trial.

Health technology assessment (Winchester, England)·2026
Same author

The Multiple Sclerosis Severity Allele rs10191329<sup>A</sup> and Cognitive Function: A UK Biobank Study.

Annals of clinical and translational neurology·2026
Same author

Early-stage type 1 diabetes: is there a role for lifestyle modifications?

The lancet. Diabetes & endocrinology·2026
Same author

An ancestry-enriched HNF4A variant and GP2 reveal distinct mechanisms of type 2 diabetes in exome-wide study of 13,674 cases and 41,024 controls.

medRxiv : the preprint server for health sciences·2026
Same author

Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Related Experiment Video

Updated: Jan 10, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.7K

Towards primary prevention of multiple sclerosis.

Ruth Dobson1,2, Karim L Kreft3,4, Benjamin M Jacobs5,6

  • 1Centre for Preventive Neurology, Wolfson Institute of Population Health, Queen Mary University London, London, UK. Ruth.dobson@qmul.ac.uk.

Nature Reviews. Neurology
|November 27, 2025
PubMed
Summary

Preventing multiple sclerosis (MS) before symptoms appear is a key goal. New strategies and trial designs are needed to overcome challenges in developing effective MS prevention interventions.

More Related Videos

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

9.7K
Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

5.1K

Related Experiment Videos

Last Updated: Jan 10, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.7K
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

9.7K
Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

5.1K

Area of Science:

  • Neurology
  • Immunology
  • Clinical Trial Design

Background:

  • Multiple sclerosis (MS) is a leading cause of disability in young adults, remaining an incurable neurological disease despite advanced therapies.
  • Preventing MS before the onset of demyelination is an ambitious but feasible objective, yet current preventive strategies lack robust efficacy evidence.
  • Challenges in MS prevention research include the low effect size of risk factors, limited intervention windows, and the disease's relatively low incidence.

Purpose of the Study:

  • To discuss the significant challenges associated with developing and evaluating preventive interventions for multiple sclerosis.
  • To propose novel strategies and solutions for MS prevention studies, drawing inspiration from advancements in other disease areas.
  • To highlight the importance of innovative trial designs, risk stratification, and outcome definitions in advancing MS prevention research.

Main Methods:

  • This perspective reviews existing literature and discusses conceptual and practical difficulties in MS prevention research.
  • It examines progress in related fields, such as studies on radiologically isolated syndrome, to inform new approaches.
  • The authors propose pragmatic strategies for risk stratification, statistical power considerations, and outcome definitions for future prevention trials.

Main Results:

  • Traditional randomized controlled trial designs face significant hurdles in the context of MS prevention.
  • Novel approaches, including studies in radiologically isolated syndrome, are generating momentum for MS prevention research.
  • Pragmatic approaches to risk stratification and careful consideration of statistical power and outcome definitions are crucial for successful intervention studies.

Conclusions:

  • Developing and testing preventive interventions for multiple sclerosis requires careful planning regarding risk stratification, communication, intervention, and outcome measures.
  • Despite the complexities, the current scientific understanding supports the urgent need to initiate MS prediction and prevention studies.
  • Innovative trial designs and strategic planning are essential to overcome the inherent difficulties in establishing effective MS prevention strategies.